Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform (Guardant Health)

Guardant Health and Pfizer have entered a multi-year global collaboration to advance Pfizer’s oncology drug development using Guardant’s liquid biopsy technologies, particularly the Guardant Infinity™ platform. The partnership will focus on utilizing circulating tumor DNA (ctDNA) to monitor therapy response and explore blood-based epigenomic analyses in clinical trials. The agreement includes access to Guardant tests in China, bolstered by Guardant’s earlier partnership with Adicon Holdings. The collaboration underscores growing interest in ctDNA as a surrogate endpoint for evaluating cancer treatment efficacy.